Sarat Chandarlapaty: HER2 ADCs and the role of EGFR in oncology
Sarat Chandarlapaty shared the following post on LinkedIn:
“HER2 ADCs continue to re-shape solid tumor oncology practice. We investigated what might limit some of their activity. In now published work in Cell Reports Medicine, with Avantika Gupta, PhD, Flavia Michelini, and several others at Memorial Sloan Kettering Cancer Center, we now find a specific role for EGFR in limiting HER2 ADC internalization and efficacy. Similar to how RTK redundancies impact RTK inhibitor efficacy—but through a very different mechanism. We find that EGFR antibodies can overcome this and promote HER2 ADC activity and are now leading investigations into this in the clinic, led by co-authors Rona Yeager and Celine Yeh.”
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Authors: Avantika Gupta, Flavia Michelini, Hong Shao, Celine Yeh, Joshua Z. Drago, Dazhi Liu, Eric Rosiek, Yevgeniy Romin, Negin Ghafourian, Sheeno Thyparambil, Sandra Misale, Wungki Park, Elisa de Stanchina, Yelena Y. Janjigian, Rona Yaeger, Bob T. Li, Sarat Chandarlapaty.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023